nach oben

Erschienen in:

01.08.2009 | Original Article

Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness

verfasst von: Giueng-Chueng Wang, Po-Shiuan Hsieh, Hsian-He Hsu, Guang-Huan Sun, Shin Nieh, Cheng-Ping Yu, Jong-Shiaw Jin

Erschienen in: World Journal of Urology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We tested the hypothesis that the expression of cortactin and survivin in renal cell carcinomas (RCCs) correlates with more advanced stages of the disease.

Methods

Immunohistochemical analysis of cortactin and survivin expression (scored on a scale of 0–400) was performed in 124 renal cell carcinomas including clear cell renal cell carcinoma (CRCC), papillary RCC (PRCC), CRCC with sarcomatoid differentiation (SRCC), chromophobe RCC (ChRCC), and CRCC with granular cell differentiation (GRCC).

Results

Higher cortactin scores in CRCC were significantly correlated with higher T (p = 0.021) and N stages (p = 0.036), and nuclear grade (p = 0.012). Higher cortactin immunostaining scores were associated with higher mortality (p = 0.035). In addition, the survivin scores were significantly higher in the more aggressive GRCC and SRCC than in CRCC, suggesting a significant role of survivin expression in transformation of tumor cells to a more malignant phenotype.

Conclusions

Higher expression of cortactin and survivin significantly correlated with advanced clinicopathological stage. Our findings support the potential targeting of survivin and cortactin for the development of novel therapeutic strategies for renal cell carcinoma.

Aznavoorian S, Murphy AN, Stetler-Stevenson WG et al (1993) Molecular aspects of tumor cell invasion and metastasis. Cancer 71:1368–1383. doi:10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L PubMedCrossRef

Bonsib SM, Gibson D, Mhoon M et al (2000) Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24:451–458. doi:10.1097/00000478-200003000-00015 PubMedCrossRef

Sweeney P, Wood CG, Pisters LL et al (2003) Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol 21:327–333. doi:10.1016/S1078-1439(02)00280-6 PubMed

Atkins MB, Regan M, McDermott D (2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10:4346S–6342S. doi:10.1158/1078-0432.CCR-040029

Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 10:6335S–6341S. doi:10.1158/1078-0432.CCR-sup-040026 PubMedCrossRef

Partin AW, Shoeniger JS, Mohler LL et al (1989) Fourier analysis of cell motility: correlation of motility with metastatic potentials. Proc Natl Acad Sci USA 86:1254–1258. doi:10.1073/pnas.86.4.1254 PubMedCrossRef

Lauffenburger DA, Horwitz AF (1996) Cell migration: a physically integrated molecular process. Cell 84:359–369. doi:10.1016/S0092-8674(00)81280-5 PubMedCrossRef

Rothschild BL, Shim AH, Ammer AG et al (2006) Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. Cancer Res 66:8017–8025. doi:10.1158/0008-5472.CAN-05-4490 PubMedCrossRef

van Rossum AG, Schuuring-Scholters E, n Seggelen V et al (2005) Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domain. BMC Genomics 6:15–17. doi:10.1186/1471-2164-6-15 PubMedCrossRef

10.

Daly RJ (2004) Cortactin signalling and dynamic actin networks. Biochem J 382:13–25. doi:10.1042/BJ20040737 PubMedCrossRef

11.

Luo ML, Shen XM, Zhang Y et al (2006) Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res 66:11690–11699. doi:10.1158/0008-5472.CAN-06-1484 PubMedCrossRef

12.

Fantozzi I, Grall D, Cagnol S et al (2008) Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression. Acta Oncol 47(8):1502–1512. doi:10.1080/02841860802089801 PubMedCrossRef

13.

Li X, Zheng H, Hara T et al (2008) Aberrant expression of cortactin and fascin are effective markers for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Int J Oncol 33(1):69–79PubMed

14.

Lin CK, Su HY, Tsai WC et al (2008) Association of cortactin, fascin-1 and epidermal growth factor receptor (EGFR) expression in ovarian carcinomas: correlation with clinicopathological parameters. Dis Markers 25(1):17–26PubMed

15.

Gibcus JH, Mastik MF, Menkema L et al (2008) Cortactin expression predicts poor survival in laryngeal carcinoma. Br J Cancer 98(5):950–955. doi:10.1038/sj.bjc.6604246 PubMedCrossRef

16.

Sah NK, Khan Z, Khan GJ et al (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164–171. doi:10.1016/j.canlet.2006.03.007 PubMedCrossRef

17.

Ambrosini G, Adida C, Altieri DC (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921. doi:10.1038/nm0897-917 PubMedCrossRef

18.

Reed JC, Bischoff JR (2000) BIRinging chromosomes through cell division—and survivin the experience. Cell 102:545–548. doi:10.1016/S0092-8674(00)00076-3 PubMedCrossRef

19.

Tran J, Master Z, Yu JL et al (2002) A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99:4349–4354. doi:10.1073/pnas.072586399 PubMedCrossRef

20.

Tran J, Rak J, Sheehan C et al (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781–788. doi:10.1006/bbrc.1999.1589 PubMedCrossRef

21.

Blanc-Brude OP, Mesri M, Wall NR et al (2003) Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 9:2683–2692PubMed

22.

Ryan BM, Konecny GE, Kahlert S et al (2006) Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597–604. doi:10.1093/annonc/mdj121 PubMedCrossRef

23.

Hidalgo A, Pina P, Guerrero G et al (2003) A simple method for the construction of a small format tissue arrays. J Clin Pathol 56:144–146. doi:10.1136/jcp.56.2.144 PubMedCrossRef

24.

Jin JS, Hsieh DS, Loh SH et al (2006) Increasing expression of serine protease matriptase in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Mod Pathol 19:447–452. doi:10.1038/modpathol.3800495 PubMedCrossRef

25.

Rosenthal EL, Shreenivas S, Peters GE et al (2003) Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 113:1406–1410. doi:10.1097/00005537-200308000-00027 PubMedCrossRef

26.

van Rossum AG, Moolenaar WH, Schuuring E (2006) Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 312:1658–1670. doi:10.1016/j.yexcr.2006.01.033 PubMedCrossRef

27.

Ormandy CJ, Musgrove EA, Hui R et al (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78:323–335. doi:10.1023/A:1023033708204 PubMedCrossRef

28.

Xiang Y, Yao H, Wang S et al (2006) Prognostic value of survivin and livin in nasopharyngeal carcinoma. Laryngoscope 116:126–130. doi:10.1097/01.mlg.0000187392.87904.35 PubMedCrossRef

29.

Zhu H, Chen XP, Zhang WG et al (2005) Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol 11:3855–3859PubMed

30.

Bhanot U, Hevdrich R, Moller P et al (2006) Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 30:754–759. doi:10.1097/00000478-200606000-00013 PubMedCrossRef

31.

Wu YK, Chen KT, Kuo YB et al (2009) Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett 273(2):331–335. doi:10.1016/j.canlet.2008.08.023 PubMedCrossRef

32.

Invernizzi R, Travaglino E, Benatti C et al (2006) Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia. Eur J Haematol 76:494–501. doi:10.1111/j.0902-4441.2006.t01-1-EJH2588.x PubMedCrossRef

33.

Antonaci A, Consorti F, Mardente S et al (2008) Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol Rep 20(1):63–67PubMed

34.

Grotty TB, Farrow GM, Lieber MM (1995) Chromophobe cell renal carcinoma, clinicopathological features of 50 cases. J Urol 154:964–967. doi:10.1016/S0022-5347(01)66944-1 CrossRef

35.

Murphy WM, Grignon DJ, Perlman EJ (2004) Chromophobe renal cell carcinoma. In: Silverberg SG and Sobin LH (eds) Atlast of tumor pathology. Tumours of the kidney, bladder, and related urinary structures, 3rd edn. AFIP, Washington, pp 130–136

36.

Moch H, Gasser T, Amin MB et al (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89:604–614. doi:10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q PubMedCrossRef

37.

Lohse CM, Blute ML, Zincke H et al (2002) Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol 118:877–886. doi:10.1309/VLV6-BRTR-HY5B-H485 PubMedCrossRef

Titel: Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness
verfasst von: Giueng-Chueng Wang
Po-Shiuan Hsieh
Hsian-He Hsu
Guang-Huan Sun
Shin Nieh
Cheng-Ping Yu
Jong-Shiaw Jin
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: World Journal of Urology / Ausgabe 4/2009
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-009-0376-2

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness